Ypsomed carves out diabetes business in $512M deal to focus on GLP-1 self-injectors

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business with a plan to trade its insulin pump development arm and rema | Ypsomed plans to trade its insulin pump arm to a new Swiss medtech, TecMed, in a deal worth up to 420 million francs or about $513 million.Read More